Adipokines in Psoriatic Arthritis Patients: The Correlations with Osteoclast Precursors and Bone Erosions

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Xue, Yu ^a   Jiang, Li ^a,b   Cheng, Qingqing ^a   Chen, Haiyan ^a   Yu, Yiyun ^a   Lin, Yinda ^a   Yang, Xue ^a   Kong, Ning ^a   Zhu, Xiaoxia ^a   Xu, Xue ^a   Wan, Weiguo ^a   Zou, Hejian ^a  

^a FUDAN UNIVERSITY   (China)

^b LINYI PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHEMERIN; CORTICOSTEROID; CYTOKINE; LEPTIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMENTIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE EROSION; CELL COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; HUMAN CELL; JOINT CAVITY; JOINT CAVITY NARROWING; JOINT CHARACTERISTICS AND FUNCTIONS; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OSSIFICATION; OSTEOCLAST; OSTEOCLAST PRECURSOR; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PSORIASIS; PSORIATIC ARTHRITIS; PSORIATIC JOINT ACTIVITY INDEX;

ADIPOKINES; ADIPONECTIN; ADULT; AGED; ANALYSIS OF VARIANCE; ARTHRITIS, PSORIATIC; BONE REMODELING; BONE RESORPTION; CHEMOKINES; CYTOKINES; FEMALE; GPI-LINKED PROTEINS; HUMANS; LECTINS; LEPTIN; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84868117008     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046740     Document Type: Article

References (50)

1. Taylor WJ, Porter GG, Helliwell PS, (2003) Operational definitions and observer reliability of the plain radiographic features of psoriatic arthritis. J Rheumatol 30: 2645-2658.
2. Frediani B, Allegri A, Falsetti P, Storri L, Bisogno S, et al. (2001) Bone mineral density in patients with psoriatic arthritis. J Rheumatol 28: 138-143.
3. Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, et al. (2007) Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol 212: 47-55.
4. Boyle WJ, Simonet WS, Lacey DL, (2003) Osteoclast differentiation and activation. Nature 423: 337-42.
5. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM, (2003) Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111: 821-831.
6. Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, et al. (2008) The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 67: 296-301.
7. Chi CM, Gary TCK, Ling YH, Ka LY, Par TC, et al. (2011) Prevalence of Atherosclerotic Risk Factors and the Metabolic Syndrome in Patients with Chronic Inflammatory Arthritis. Arch Dermatol Res 303: 451-455.
8. Kontny E, Plebanczyk M, Lisowska B, Olszewska M, Maldyk P, et al. (2012) Comparison of rheumatoid articular adipose and synovial tissue reactivity to proinflammatory stimuli: contribution to adipocytokine network. Ann Rheum Dis 71: 262-267.
9. Liu L, Yang P, He H, Lin X, Jiang L, et al. (2008) Leptin increases in Vogt-Koyanagi-Harada (VKH) disease and promotes cell proliferation and inflammatory cytokine secretion. Br J Ophthalmol 92: 557-561.
10. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, et al. (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54: 2665-2673.
11. Gladman DD, Tom BD, Mease PJ, Farewell VT, (2008) Response criteria for psoriatic arthritis II: Developing and comparing response criteria for PsA. Ann Rheum Dis 67 (Suppl II):: 526.
12. Gladman DD, Psaradellis F, Illouz O, Sampalis JS, (2009) Evaluation of response using the Psoriatic Arthritis Joint Activity Index scoring tool in patients treated with adalimumab: Post-hoc analysis of the ACCLAIM study. J Rheumatol 36: 2571.
13. van der Heijde D, Kavanaugh A, Gladman DD, Antoni C, Krueger GG, et al. (2007) Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 56: 2698-2707.
14. Mackay K, Mack C, Brophy S, Calin A, (1998) The bath ankylosing spondylitis radiology index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 41: 2263-2270.
15. Calin A, Mackay K, Brophy S, (1999) A new dimension to outcome: application of the bath ankylosing spondylitis radiology index. J Rheumatol 26: 988-992.
16. Dalbeth N, Smith T, Nicolson B, Clark B, Callon K, et al. (2008) Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells. Arthritis Rheum 58: 1854-1865.
17. Maruotti N, Grano M, Colucci S, d'Onofrio F, Cantatore FP, (2011) Osteoclastogenesis and arthritis. Clin Exp Med 11: 137-145.
18. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, et al. (1997) Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 6: 1349-1356.
19. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, et al. (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25: 1544-1552.
20. Anandarajah AP, Ritchlin C, (2004) Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 16: 338-343.
21. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, et al. (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64: 1150-1157.
22. Mease PJ, Kivitz AJ, Burch FX, Seigel EL, Cohen SB, et al. (2004) Etanercept treatment of psoriatic arthritis, safety, efficacy, and effect on disease progression. Arthritis Rheum 50: 2264-2272.
23. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, et al. (2005) Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52: 3279-3289.
24. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, et al. (2008) Psoriasis Work Group. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guideline of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58: 851-864.
25. Neumann E, Frommer K, Vasile M, Muller-Ladner U, (2011) Adipocytokines as driving forces in rheumatic diseases. Arthritis Rheum 63: 1159-1169.
26. Palmer G, Gabay C, (2003) A role for leptin in rheumatic diseases? Ann Rheum Dis 62: 913-915.
27. Cerman AA, Bozkurt S, Sav A, Tulunay A, Elbasi MO, et al. (2008) Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 159: 820-826.
28. Otero M, Logo R, Gomez R, Lago F, Diequez C, et al. (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Annals of the rheumatic diseases 65: 1198-1201.
29. Dumond H, Presle N, Terlain B, Mainard D, Loeuille D, (2003) Evidence for a key role of leptin in osteoarthritis. Arthritis and Rheumatism 48: 3118-3129.
30. Hideki N, Kimiko N, Masahito T, Ryuji M, Shigetoshi S, (2011) Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients. Arch Dermatol Res 303: 451-455.
31. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, et al. (2003) Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 198: 977-985.
32. Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, et al. (2005) Chemerin activation by serine proteases of the coagulation, fibrinolytic and inflammatory cascades. J Biol Chem 280: 34661-34666.
33. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, et al. (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148: 4687-4694.
34. Luangsay S, Wittamer V, Bondue B, De Henau O, Rouger L, et al. (2009) Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. J Immunol 183: 6489-6499.
35. Kaur J, Adya R, Tan BK, Chen J, Randeva HS, (2010) Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun 391: 1762-1768.
36. Berg V, Sveinbjornsson B, Bendiksen S, Brox J, Meknas K, et al. (2010) Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin(21-157). Arthritis Res Ther 12: R228.
37. Conde J, Gomez R, Bianco G, Scotece M, Lear P, et al. (2011) Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. Ann Rheum Dis 70: 551-559.
38. Vermi W, Riboldi E, Wittamer V, Gentili F, Luini W, et al. (2005) Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med 201: 509-515.
39. Muruganandan S, Roman AA, Sinal CJ, (2010) Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells. J Bone Miner Res 25: 222-34.
40. Gerwick L, Corley-Smith G, Bayne CJ, (2007) Gene transcript changes in individual rainbow trout livers following an inflammatory stimulus. Fish and Shellfish Immunol 22: 157-171.
41. Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, et al. (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56: 1655-1661.
42. Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J, et al. (2005) Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 1732: 96-102.
43. Ladislav Š, Markéta P, Maria F, Lucie Andrés C, Karel P, et al. (2010) Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann Rheum Dis 69: 1410-1411.
44. Bokarewa M, Nagaev L, Dahlberg L, Smith U, Tarkowski A, (2005) Resistin, an adipokine with potent proinflammatory properties. J immunol 174: 5789-5795.
45. Corbetta S, Angioni R, Cattaneo A, Beck-Peccoz P, Spada A, (2006) Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 154: 83-86.
46. Forsblad d'Elia H, Pullerits R, Carlsten H, Bokarewa M, (2008) Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford) 47: 1082-1087.
47. Senolt L, Housa D, Vernerova Z, Jirasek T, Svobodova R, et al. (2007) Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 66: 458-463.
48. Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriquez TR, et al. (2008) Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol 26: 311-316.
49. Lee JH, Ort T, Ma K, Picha K, Carton J, et al. (2009) Resistin is elevated following traumatic joint injury and causes matrix degradation and release of inflammatory cytokines from articular cartilage in vitro. Osteoarthritis Cartilage 17: 613-620.
50. Zhang Z, Xing X, Hensley G, Chang LW, Liao W, et al. (2010) Resistin induces expression of proinflammatory cytokines and chemokines in human articular chondrocytes via transcription and messenger RNA stabilization. Arthritis Rheum 62: 1993-2003.